April 15, 2020

COVID-19 Healthcare Disparities Information

Across the country, the COVID-19 pandemic is disproportionately affecting vulnerable communities, particularly African Americans.

African Americans comprise approximately 13% of the population in the United States but according to the hospital data from the first month of the U.S. epidemic released by the Centers for Disease Control and Prevention (*attached below), nearly 33% of African Americans were hospitalized. In addition, 90% of all the patients (including African Americans) admitted to the hospital had an underlying health condition. The most common conditions were hypertension, obesity, chronic lung disease, and diabetes mellitus. Unfortunately, African Americans are more likely to develop these chronic conditions which can impair their immune system leading to further complications from viruses such as COVID-19.

Less access to healthcare, unemployment, lack of affordable and healthy food in their neighborhoods are some of the reasons that lead to detrimental health outcomes for many African Americans. COVID-19 is not novel in highlighting the enormous amount of health disparities in the United States amongst African Americans, this is the same story for diseases such as Alzheimer's.

To help address the disparities in the Greater Boston area, Partners Community Health has launched a new COVID-19 Strategy with four main goals:

-Expanding testing to better identify COVID-19 positive individuals in these communities
-Mitigating the spread of COVID-19 with door-to-door distribution of multilingual information and “care kits” with masks and other key items
-Identifying housing and support mechanisms for those individuals who are COVID-19 positive but cannot safely isolate at home without the risk of spread
-Creating routine channels of communication with community members, using care managers and community health workers, to focus on COVID-19 positive individuals and those at-risk to assess ability to isolate, symptoms and the need for additional service

The Partners COVID-19 Hotline can be reached at 617-724-7000. Links to additional resources are located below:

For information on how the Massachusetts Alzheimer’s Disease Research Center is addressing healthcare disparities in research participation, contact:

March 26, 2020


Due to concerns surrounding COVID-19, we are taking every precaution to protect our research participants, study partners, and staff. We have shut down our in-house research operations, including clinical trials.  Our staff are working remotely from their homes and participants and study partners are not coming in for visits. For some studies, we are continuing to perform remote visits that consist of either phone calls with our staff or computerized tests that can be done from home. Our dedication to finding more effective treatments and a cure for Alzheimer’s disease continues as always, however we must focus on the medical crisis at hand and follow all recommended guidelines to keep people safe. 


We do not know yet when we will resume normal operations. We are evaluating the situation on a weekly basis and are available via phone and email in the meantime.


Partners Healthcare has set up a COVID-19 hotline for clinicians, patients and the public at 617-724-7000.  For the most accurate updates on COVID-19, visit: and/or

September 18, 2019

2021 Massachusetts General Hospital Clinical Fellowship in Dementia

The Massachusetts Alzheimer's Disease Research Center (ADRC) is pleased to announce an opening for a two-year Clinical  Fellowship in Dementia at the Massachusetts General Hospital (MGH) and related institutions beginning July 1, 2021.

The goal of the non-degree program is to introduce exceptionally-qualified individuals to the successes and demands of a clinical career in dementia and related neurodegenerative diseases, and to provide an unparalleled foundation for potential leadership roles in academic medicine, industry or related fields.

More information is attached.

Fellowship application deadline:  July 1, 2020

September 2, 2019

Biogen Aducanumab

Thank you for being in touch about the recent Biogen announcement. We understand you have many questions about it and thank you for your patience. At this time, the information we have is similar to what you have read and heard.

There is a scientific meeting scheduled for December at which more data will be presented by the company. We expect to have more information after this meeting and will keep our patients and their family members updated as information continues to become available. We are working on providing live updates on our website and will share the information to access this as soon as we have it. The aducanumab trial is not currently enrolling patients.

June 2, 2017

2017 Center of Excellence for Delirium in Aging: Research, Training and Educational Enhancement Delirium Research Boot Camp

Our colleagues at the Center of Excellence for Delirium in Aging:  Research, Training & Educational Enhancement (CEDARTREE) are offering their 5th 'delirium boot camp' in Boston from November 1-3, 2017 and we'll love to help them get the word out:

The 3-day intensive course on delirium research will be held at the Inn at the Longwood Medical Center (342 Longwood Avenue, Boston, MA 02115) and recognized experts in the field will discuss cutting-edge research approaches, from assessment and methodology to novel technologies and interventions. Attendees will also have the opportunity to network with world-renowed experts in delirium and related fields.

More information regarding the boot camp and eligibility to attend may be found at

A copy of the boot camp's application form is attached.